ASCO 2023 | MonumenTAL-1: incidence of severe infections & parameters of humoral immunity with talquetamab
Paula Rodriguez Otero, MD, PhD, University Clinic of Navarra, Pamplona, Spain, comments on an analysis from the MonumenTAL-1 (NCT03399799) study investigating the incidence of severe infections and parameters of humoral immunity in patients with relapsed/refractory (R/R) multiple myeloma treated with talquetamab monotherapy. The study reported that there was better preservation of B-cell immunity in patients treated with talquetamab when compared to patients treated with BCMA-directed bispecifics, which might explain the lower rate of severe infections in patients treated with talquetamab.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria from lectures: BMS, Janssen, Sanofi, GSK, Amgen, Regeneron and Takeda
Participation in Ad Board meetings: BMS, Janssen, Sanofi, Kite Pharma, Abbvie, Oncopeptides, Takeda, Pfizer and GSK
Consultant: BMS, Abbvie, Roche and Pfizer
Research funding: none
